ArticleJournal of hepatocellular carcinoma2025
Clinical Implications and Novel Insights into Adolescent Primary Liver Cancer: A Nightmare for Adolescents?
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Machine learning-based early survival prediction in early-onset hepatocellular carcinoma: a SEER-based multi-model comparative study.Translational cancer research · 2026Article
- Clinical-pathological characteristics and prognosis of elderly primary liver cancer patients.American journal of cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study retrospectively analyzed clinical data from adolescent primary liver cancer (PLC) cases over the past decade, summarizing clinical characteristics, diagnostic approaches, and prognostic outcomes to provide guidance for prevention, early diagnosis, and timely treatment of adolescent PLC. Methods: Clinical data of 497 cases of adolescent PLC patients were collected from January 1, 2014, to December 31, 2024. The baseline demographic data, general condition, imaging, laboratory findings, and pathological features of these patients were described, and the diagnostic and therapeutic processes were analyzed, univariate and multivariate Cox regression analyses were conducted to identify significant prognostic factors. Results: The age of onset for patients was 13.75 (10.25-19.00) years, with 311 males (62.58%) and 186 females (37.42%), yielding a male-to-female ratio of 1.67:1. Elevated ALT and GGT levels were observed in most patients, while all patients exhibited elevated ChE. Among all patients included in this study, 320 cases (64.39%) were infected with HBV, 469 cases (94.36%) were diagnosed with hepatocellular carcinoma (HCC), 14 cases (2.82%) with intrahepatic cholangiocarcinoma, and 14 cases (2.82%) with mixed hepatocellular-intrahepatic cholangiocarcinoma. The follow-up results showed the 1-year, 2-year, and 3-year survival rates in adolescent PLC patients were 45.27%, 20.32%, and 8.45%, respectively. The univariate Cox regression analysis revealed that adolescent PLC patients who accompanied with portal vein tumor thrombus, ascites, advanced CNLC stage, abnormalities in AFP, ALT, AST, AST/ALT ratio, GGT, ALP and TBIL, high ECOG score and non-surgical treatment had shorter OS ( Conclusion: Clinical manifestations and symptoms of adolescent PLC patients lack specificity, and portal vein tumor thrombus, advanced CNLC stage, abnormalities in AFP, GGT, and non-surgical treatment were independent prognostic factors influencing OS in adolescent PLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.